Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**L-glutaminase** is an enzyme (amidohydrolase, EC 3.5.1.2) that catalyzes the hydrolysis of L-glutamine to L-glutamate and ammonia. It is studied and applied primarily as an *anticancer agent*, depleting L-glutamine in the extracellular environment, which inhibits the proliferation and survival of cancer cells that rely heavily on glutamine for metabolic functions and growth[3][4]. The enzyme's cytotoxic and anticancer effects have been shown in various cancer cell lines (e.g., leukemia, breast, colorectal, liver cancers), where glutaminase-mediated glutamine deprivation promotes cell death, protein synthesis arrest, and oxidative stress[3][4]. L-glutaminase is sourced from microbes (e.g., Streptomyces, Klebsiella, Halomonas, Alcaligenes, Pseudomonas), and microbial forms are preferred for large-scale production due to cultivation efficiency. L-glutaminase also has industrial relevance as a flavor enhancer, contributing to umami taste[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-glutaminase.